Style | Citing Format |
---|---|
MLA | Shahnazari S, et al.. "Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran." Iranian Journal of Kidney Diseases, vol. 19, no. 1, 2025, pp. 30-40. |
APA | Shahnazari S, Mehrazma M, Feli SN, Ossareh S (2025). Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran. Iranian Journal of Kidney Diseases, 19(1), 30-40. |
Chicago | Shahnazari S, Mehrazma M, Feli SN, Ossareh S. "Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran." Iranian Journal of Kidney Diseases 19, no. 1 (2025): 30-40. |
Harvard | Shahnazari S et al. (2025) 'Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran', Iranian Journal of Kidney Diseases, 19(1), pp. 30-40. |
Vancouver | Shahnazari S, Mehrazma M, Feli SN, Ossareh S. Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran. Iranian Journal of Kidney Diseases. 2025;19(1):30-40. |
BibTex | @article{ author = {Shahnazari S and Mehrazma M and Feli SN and Ossareh S}, title = {Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran}, journal = {Iranian Journal of Kidney Diseases}, volume = {19}, number = {1}, pages = {30-40}, year = {2025} } |
RIS | TY - JOUR AU - Shahnazari S AU - Mehrazma M AU - Feli SN AU - Ossareh S TI - Evaluation of Long-Term Outcomes and Its Related Factors in Patients With Immune-Complex Mediated Glomerulonephritis: A 20-Year Historical Cohort Study in Iran JO - Iranian Journal of Kidney Diseases VL - 19 IS - 1 SP - 30 EP - 40 PY - 2025 ER - |